Green Lifescience Past Earnings Performance
Past criteria checks 0/6
Green Lifescience's earnings have been declining at an average annual rate of -58.3%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been declining at an average rate of 4.4% per year.
Key information
-58.3%
Earnings growth rate
-57.6%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | -4.4% |
| Return on equity | -45.5% |
| Net Margin | -73.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Green Lifescience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 22,369 | -16,358 | 2,046 | 112 |
| 30 Sep 23 | 23,129 | -5,177 | 1,918 | 114 |
| 30 Jun 23 | 22,314 | -5,058 | 1,965 | 201 |
| 31 Mar 23 | 25,900 | -4,513 | 1,569 | 427 |
| 31 Dec 22 | 36,505 | -3,526 | 1,992 | 426 |
| 30 Sep 22 | 39,978 | -2,267 | 2,136 | 461 |
| 30 Jun 22 | 39,758 | -2,696 | 2,210 | 348 |
| 31 Mar 22 | 34,441 | -2,524 | 2,326 | 110 |
| 31 Dec 21 | 25,338 | -3,136 | 2,102 | 110 |
| 30 Sep 21 | 22,361 | -2,615 | 1,734 | 0 |
| 30 Jun 21 | 21,203 | -1,928 | 1,755 | 0 |
| 31 Mar 21 | 24,440 | -854 | 1,741 | 0 |
| 31 Dec 20 | 24,561 | -1,059 | 1,699 | 0 |
| 30 Sep 20 | 28,036 | -8 | 1,953 | 0 |
| 30 Jun 20 | 31,875 | 428 | 1,834 | 0 |
| 31 Mar 20 | 33,657 | 140 | 1,919 | 0 |
| 31 Dec 19 | 37,618 | 1,196 | 2,204 | 0 |
| 30 Sep 19 | 34,305 | -601 | 2,095 | 0 |
| 30 Jun 19 | 34,030 | -815 | 2,167 | 0 |
| 31 Mar 19 | 31,294 | -1,551 | 2,181 | 0 |
| 31 Dec 18 | 32,754 | -1,445 | 1,996 | 0 |
| 30 Sep 18 | 36,947 | -607 | 2,119 | 0 |
| 30 Jun 18 | 39,978 | 433 | 2,230 | 0 |
| 31 Mar 18 | 42,115 | 953 | 2,317 | 0 |
| 31 Dec 17 | 42,585 | 2,225 | 2,209 | 0 |
| 30 Sep 17 | 41,665 | 4,081 | 2,110 | 0 |
| 30 Jun 17 | 43,515 | 4,408 | 2,053 | 0 |
| 31 Mar 17 | 46,117 | 5,239 | 2,237 | 0 |
| 31 Dec 16 | 43,304 | 4,504 | 2,307 | 0 |
| 30 Sep 16 | 46,740 | 5,882 | 2,341 | 0 |
| 30 Jun 16 | 46,153 | 5,667 | 2,451 | 0 |
| 31 Mar 16 | 46,219 | 5,661 | 2,234 | 0 |
| 31 Dec 15 | 45,508 | 5,387 | 2,211 | 0 |
| 30 Sep 15 | 43,593 | 2,262 | 2,091 | 0 |
| 30 Jun 15 | 42,141 | 1,075 | 1,941 | 0 |
| 31 Mar 15 | 35,198 | -243 | 1,880 | 0 |
| 31 Dec 14 | 37,081 | -1,062 | 2,043 | 0 |
| 30 Sep 14 | 36,940 | -1,623 | 1,839 | 0 |
| 30 Jun 14 | 32,982 | -2,176 | 1,913 | 0 |
| 31 Mar 14 | 34,966 | -1,614 | 1,965 | 0 |
| 31 Dec 13 | 34,526 | -1,312 | 2,065 | 0 |
| 30 Sep 13 | 42,860 | -124 | 2,941 | 0 |
| 30 Jun 13 | 48,627 | 1,940 | 2,992 | 0 |
Quality Earnings: A114450 is currently unprofitable.
Growing Profit Margin: A114450 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A114450 is unprofitable, and losses have increased over the past 5 years at a rate of 58.3% per year.
Accelerating Growth: Unable to compare A114450's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A114450 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.5%).
Return on Equity
High ROE: A114450 has a negative Return on Equity (-45.5%), as it is currently unprofitable.